Product Information

BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE is a generic product labeled by H2-Pharma LLC, priced at $2.4028 per EA under NDC 61269038512. Its NADAC has been published 131 times since Apr 3, 2024.

FDA first approved this application on Sep 28, 2006. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE

BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, AND TETRACYCLINE HYDROCHLORIDE
$2.4028per EA
Discontinued

Strength

140; 125; 125 mg/1; mg/1; mg/1

Manufacturer

H2-Pharma LLC

NDC

61269038512

Classification

Generic

Dosage Form

CAPSULE

Route

ORAL

Effective Date

9/23/2026

Approval Type

New Drug (NDA)

FDA Application

NDA050786

FDA Approved

9/28/2006

TE Code

AB

On Market Since

7/31/2023

Pharmacological Classes

Price Statistics

The NADAC for BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE has been published 131 times since Apr 3, 2024, and over the history we have for it it has declined 46.2%. The table below summarizes its recorded NADAC range and movement.

Current price$2.4028 per EA
All-time high$4.4687 (Apr 10, 2024)
All-time low$2.3760 (Aug 19, 2026)
52-week high$3.6473
52-week low$2.3760
Median price$3.5583
Average price$3.4274
Largest weekly change-22.6% (Jul 17, 2024)
Weeks tracked131
Tracking sinceApr 3, 2024

Price History

1W

0.0%

1M

+1.1%

3M

+0.5%

6M

-23.8%

1Y

-34.1%

3Y

N/A

5Y

N/A

All

-46.2%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, AND TETRACYCLINE HYDROCHLORIDE market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE?

The current National Average Drug Acquisition Cost (NADAC) for BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE, manufactured by H2-Pharma LLC, is $2.4028 per EA (NDC 61269038512), effective Sep 30, 2026.

How has the price of BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE changed over time?

Over the history we have for it, the NADAC for BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE has declined 46.2%. It has been tracked across 131 weekly CMS publications since Apr 3, 2024.

What are the highest and lowest recorded NADAC prices for BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE?

Since Apr 3, 2024, the NADAC for BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE has ranged from a low of $2.3760 (Aug 19, 2026) to a high of $4.4687 (Apr 10, 2024), with a median of $3.5583 per EA.

Are there cheaper alternatives to BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE?

No other NADAC-published product currently shares the active ingredient and strength of BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE?

BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE (NDC 61269038512) is labeled by H2-Pharma LLC, and CMS classifies it as a generic product.